All Articles
Diagnostic Commercialization and Development Budget Allocation

Diagnostic Commercialization and Development Budget Allocation

9 November, 2015

In the final part of the series 'Personalized Medicine: What Pharma Should Do to Get Ready', Tessa Sandberg discusses the importance of allocating a large enough budget for diagnostic development and commercialization to support the goal of becoming a leader in the field of personalized medicine.|In the final part of the series 'Personalized Medicine: What Pharma Should Do to Get Ready', Tessa Sandberg discusses the importance of allocating a large enough budget for diagnostic development and commercialization to support the goal of becoming a leader in the field of personalized medicine.|In the final part of the series 'Personalized Medicine: What Pharma Should Do to Get Ready', Tessa Sandberg discusses the importance of allocating a large enough budget for diagnostic development and commercialization to support the goal of becoming a leader in the field of personalized medicine.|In the final part of the series 'Personalized Medicine: What Pharma Should Do to Get Ready', Tessa Sandberg discusses the importance of allocating a large enough budget for diagnostic development and commercialization to support the goal of becoming a leader in the field of personalized medicine.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.